These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 23899238)

  • 1. Rationale and early clinical data on IL-17 blockade in psoriasis.
    Nwe SM; Champlain AH; Gordon KB
    Expert Rev Clin Immunol; 2013 Jul; 9(7):677-82. PubMed ID: 23899238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis.
    Jeon C; Sekhon S; Yan D; Afifi L; Nakamura M; Bhutani T
    Hum Vaccin Immunother; 2017 Oct; 13(10):2247-2259. PubMed ID: 28825875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of IL 23 in the treatment of psoriasis.
    Puig L
    Expert Rev Clin Immunol; 2017 Jun; 13(6):525-534. PubMed ID: 28165883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL-17 and IL-17R: an auspicious therapeutic target for psoriatic disease.
    Mitra A; Raychaudhuri SK; Raychaudhuri SP
    Actas Dermosifiliogr; 2014 Oct; 105 Suppl 1():21-33. PubMed ID: 25398489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Role of IL-17 in the Pathogenesis of Psoriasis and Update on IL-17 Inhibitors for the Treatment of Plaque Psoriasis.
    AbuHilal M; Walsh S; Shear N
    J Cutan Med Surg; 2016 Nov; 20(6):509-516. PubMed ID: 27207350
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of brodalumab for the treatment of psoriasis and psoriatic arthritis.
    Kivelevitch DN; Menter A
    Immunotherapy; 2015; 7(4):323-33. PubMed ID: 25917624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic implications of IL-17A blockade in psoriasis.
    Puig L; Carrascosa JM
    Actas Dermosifiliogr; 2014 Oct; 105 Suppl 1():1-5. PubMed ID: 25398486
    [No Abstract]   [Full Text] [Related]  

  • 8. The role of IL-17 in psoriasis.
    Malakouti M; Brown GE; Wang E; Koo J; Levin EC
    J Dermatolog Treat; 2015 Feb; 26(1):41-4. PubMed ID: 24552504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti IL-17 in psoriasis.
    Ly K; Smith MP; Thibodeaux Q; Reddy V; Liao W; Bhutani T
    Expert Rev Clin Immunol; 2019 Nov; 15(11):1185-1194. PubMed ID: 31603358
    [No Abstract]   [Full Text] [Related]  

  • 10. Interleukin 17A: toward a new understanding of psoriasis pathogenesis.
    Lynde CW; Poulin Y; Vender R; Bourcier M; Khalil S
    J Am Acad Dermatol; 2014 Jul; 71(1):141-50. PubMed ID: 24655820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biologic Therapy in Psoriasis (Part II): Efficacy and Safety of New Treatment Targeting IL23/IL-17 Pathways.
    Molinelli E; Campanati A; Brisigotti V; Offidani A
    Curr Pharm Biotechnol; 2017; 18(12):964-978. PubMed ID: 29299984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin-23 and interleukin-17: importance in pathogenesis and therapy of psoriasis.
    Mudigonda P; Mudigonda T; Feneran AN; Alamdari HS; Sandoval L; Feldman SR
    Dermatol Online J; 2012 Oct; 18(10):1. PubMed ID: 23122008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systematic review of interleukin-12, interleukin-17, and interleukin-23 pathway inhibitors for the treatment of moderate-to-severe chronic plaque psoriasis: ustekinumab, briakinumab, tildrakizumab, guselkumab, secukinumab, ixekizumab, and brodalumab.
    Tausend W; Downing C; Tyring S
    J Cutan Med Surg; 2014; 18(3):156-69. PubMed ID: 24800703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-17 (IL-17) inhibitors in the treatment of plaque psoriasis: a review.
    Gooderham M; Posso-De Los Rios CJ; Rubio-Gomez GA; Papp K
    Skin Therapy Lett; 2015; 20(1):1-5. PubMed ID: 25807214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathogenic role of IL-17 in psoriasis and psoriatic arthritis.
    Chiricozzi A
    Actas Dermosifiliogr; 2014 Oct; 105 Suppl 1():9-20. PubMed ID: 25398488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tildrakizumab for treating psoriasis.
    Galluzzo M; D'adamio S; Bianchi L; Talamonti M
    Expert Opin Biol Ther; 2017 May; 17(5):645-657. PubMed ID: 28271735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biologics that inhibit the Th17 pathway and related cytokines to treat inflammatory disorders.
    Balato A; Scala E; Balato N; Caiazzo G; Di Caprio R; Monfrecola G; Raimondo A; Lembo S; Ayala F
    Expert Opin Biol Ther; 2017 Nov; 17(11):1363-1374. PubMed ID: 28791896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ixekizumab for treatment of psoriasis.
    Dyring-Andersen B; Skov L; Zachariae C
    Expert Rev Clin Immunol; 2015 Apr; 11(4):435-42. PubMed ID: 25748485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting IL-17 with ixekizumab in patients with psoriasis.
    Dyring-Andersen B; Skov L; Zachariae C
    Immunotherapy; 2015; 7(9):957-66. PubMed ID: 26569072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of emerging immunotherapies in psoriasis.
    Yiu ZZ; Warren RB
    Immunotherapy; 2015; 7(2):119-33. PubMed ID: 25713988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.